Program
ABBV-932
A development code.
In AbbVie's pipeline, D3/ D2/ 5-HT1A receptor partial agonist
. Its studies are mostly in Generalized Anxiety Disorder · Bipolar Disorder, led by AbbVie.
Furthest: phase 2, since Sep 18, 202410 company-led studies, 3 open or runningNext primary completion: Nov 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 103 open or running | phase 2since Sep 18, 2024 | Feb 13, 2023 | Nov 2026phase 2 · NCT06846320 |
- Named in AbbVie’s own pipeline as
ABBV-932
, phase 2, as of Jul 30, 2026 (source).
Also a collaborator on its studies: gedeon-richter-plc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 13, 2023First study: phase 1 study in Generalized Anxiety DisorderFirst studyNCT05738850 · 104 enrolled · United States
- Aug 30, 2023Phase 1 study in Generalized Anxiety DisorderNCT06024239 · 72 enrolled · United States
- Mar 3, 2024Phase 1 study in Healthy VolunteersNCT06300580 · 11 enrolled · United Kingdom
- Sep 18, 2024Phase 2 study in Bipolar DisorderNCT06605599 · 161 enrolled · United States, Japan, Puerto Rico
- Feb 21, 2025Phase 2 study in Generalized Anxiety DisorderNCT06846320 · 315 planned · United States, Puerto Rico
- Feb 24, 2025Phase 1 study in Healthy VolunteerNCT06849791 · 9 enrolled · United States
- Apr 24, 2025Phase 1 study in Healthy VolunteerNCT06953934 · 8 enrolled · Netherlands
- Jun 9, 2025Phase 1 study in Healthy VolunteerNCT07024797 · 20 enrolled · China
- Jul 8, 2025Phase 1 study in Bipolar DisorderNCT07071532 · 20 planned · United States
- Sep 26, 2025Phase 2 study in Bipolar I or II DisorderNCT07220460 · 84 enrolled · United States, Puerto Rico
Ahead
- Nov 2026Primary completion: phase 2 study in Generalized Anxiety DisorderNCT06846320
- Feb 2027Primary completion: phase 1 study in Bipolar DisorderNCT07071532
- Mar 2027Primary completion: phase 2 study in Bipolar I or II DisorderNCT07220460
TargetBeta
“D3/ D2/ 5-HT1A receptor partial agonist”the company's pipeline, read by Claude · source
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07220460Bipolar I or II Disorder · United States, Puerto Rico | 2 | Active, not recruiting | Mar 2027 | 84 |
| NCT07071532Bipolar Disorder · United States | 1 | Recruiting | Feb 2027 | 20 |
| NCT07024797Healthy Volunteer · China | 1 | Completed | Dec 8, 2025 | 20 |
| NCT06953934Healthy Volunteer · Netherlands | 1 | Completed | Sep 14, 2026 | 8 |
| NCT06849791Healthy Volunteer · United States | 1 | Completed | May 8, 2026 | 9 |
| NCT06846320Generalized Anxiety Disorder · United States, Puerto Rico | 2 | Recruiting | Nov 2026 | 315 |
| NCT06605599Bipolar Disorder · United States, Japan, Puerto Rico | 2 | Completed | Nov 12, 2025 | 161 |
| NCT06300580Healthy Volunteers · United Kingdom | 1 | Completed | May 26, 2025 | 11 |
| NCT06024239Generalized Anxiety Disorder · United States | 1 | Completed | Mar 4, 2025 | 72 |
| NCT05738850Generalized Anxiety Disorder · United States | 1 | Completed | May 31, 2024 | 104 |
How it is read
Names in the registry
- “ABBV-932”, 11 entries
Codes read as this program: ABBV932.
Conditions, from the studies’ own filings
- Generalized Anxiety Disorder, 3 studies
- Bipolar Disorder, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.